---
document_datetime: 2024-10-24 14:37:45
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/onbevzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: onbevzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5409481
conversion_datetime: 2025-12-19 06:41:23.140305
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0005              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 13/02/2023                                  | 09/03/2023                                  | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Onbevzi Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/403/2 02202   | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/10/2022   | 09/12/2022   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) ' for PSUSA/403/202202.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0004/G           | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                | 21/07/2022   | 09/12/2022   | SmPC and PL   | longer authorised                                                                                                                           |
| PSUSA/403/2 02102   | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/09/2021   | n/a no       |               | PRAC Recommendation - maintenance                                                                                                           |
| WS/2040/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by Medicinal product | 06/05/2021   | 24/06/2022   | SmPC and PL   |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->